A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion

NCT04123886 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Pleural Effusion

Interventions

DRUG: SCB-313

Sponsor

Sichuan Clover Biopharmaceuticals, Inc.